VRTX241213P440000
- 0.05
- -1.55-96.88%
Vertex Pharmaceuticals Newsroom
Weekly Buzz: Tech stocks hit high scores on ominous day
Market Mixed on Friday the 13th | Livestock
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Thursday Ends in Index Declines | Wall Street Today
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $525
TD Cowen Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Market Falls Wednesday, but Googles Chip Impresses | WST
10 Health Care Stocks With Whale Alerts In Today's Session
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Jefferies follows JPMorgan's call on Vertex Pharmaceuticals (VRTX.US) and raises the target price to $550.
Based on fundamentals and product pipeline, jefferies financial has upgraded vertex pharmaceuticals to buy.
Vertex Upgraded to Buy by Jefferies on Fundamentals, Pipeline
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Vertex Reports Positive Long-term Data for Casgevy
Monday Market Falls, Chinese Stocks Climb, Indices Rebalance | Live Stock
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts
Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies
Vertex Pharmaceuticals Analyst Ratings